Administration of recombinant Gal-1 to mice with IgE-mediated allergic conjunctivitis showed divided results; on the one hand, Gal-1 treatment led to resolution of clinical signs of conjunctivitis and reduced Th2 cytokines (IL-4 and IL-13) and chemokines (eotaxin and CCL5) but resulted in eosinophilia in the conjunctiva with increased Gal-1 expression in the epithelium of the bulbar conjunctiva relative to untreated mice (94). The gene discussed is LGALS1; the disease is conjunctivitis.